The Adiministrative and Mentoring Core will be responsible for all fiscal activities related to the COBRE program, including the placement of all orders and providing financial reports to the module directors and investigators. Dr. Dhanasekaran will direct the Adiministrative and Mentoring Core, which will provide all administrative functions of the COBRE program. He will be assisted by a Business Administrator and a Staff Assistant. The Business Administrator, Mr. Bobby Thomas (25%), will oversee the activities of an Administrative Assistant, Ms. Alisha Booth (100%). Mr. Thomas has been with the OUHSC for 10 years and is very convensant with the fiscal and grant management policies of OUHSC and federal funding agencies including NIH. Mr. Thomas will meet monthly with each investigator to review their accounts and mentor them in the fiscal management of sponsored research grants. Salaries for the PI, administrative staff, mentoring faculty, core directors will be paid through this core module. In addition, this core will administer the fiscal accounting for the proposed pilot projects. Coordinating meetings, travel and activities of the Internal Advisory Committee and the External Advisory Committee will be the responsibility of the Administrative Assistant, Ms. Booth, under the direction of the PI.

Public Health Relevance

Cancer represents a major health burden in the US. Ultimately, alleviating the burden of cancer will come from research: the generation of new ideas and, consequently, the development of novel agents. A COBRE grant will allow the Oklahoma Cancer Center to provide PJIs a focused mentoring experience to help them mature into independently-funded investigators contributing to the overall fight against cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
7P20GM103639-05
Application #
9099942
Study Section
Special Emphasis Panel (ZRR1)
Project Start
Project End
Budget Start
2016-06-01
Budget End
2017-05-31
Support Year
5
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Type
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Liu, Xuan; Shen, Tao; Mooers, Blaine H M et al. (2018) Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol 175:3504-3515
Boswell-Casteel, Rebba C; Johnson, Jennifer M; Hays, Franklin A (2018) Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1). Molecules 23:
Jaiprasart, Pharavee; Yeung, Bertrand Z; Lu, Ze et al. (2018) Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. J Control Release 270:101-113
Buechel, Megan; Dey, Anindya; Dwivedi, Shailendra Kumar Dhar et al. (2018) Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther 17:2136-2143
Ha, Ji Hee; Radhakrishnan, Rangasudhagar; Jayaraman, Muralidharan et al. (2018) LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res 78:1923-1934
Dey, Anindya; Xiong, Xunhao; Crim, Aleia et al. (2018) Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther 17:39-49
Boswell-Casteel, Rebba C; Johnson, Jennifer M; Roe-Žurž, Zygy et al. (2018) Expression and purification of human and Saccharomyces cerevisiae equilibrative nucleoside transporters. Protein Expr Purif 142:68-74
Jiao, Yang; Watts, Tanya; Xue, Jing et al. (2018) Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1. BMC Cancer 18:1042
Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249
Amreddy, Narsireddy; Babu, Anish; Panneerselvam, Janani et al. (2018) Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine 14:373-384

Showing the most recent 10 out of 68 publications